[EN] 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS [FR] ANALOGUES DE QUINAZOLIN-4-YLAMINE 2-SUBSTITUEE COMME MODULATEURS DES RECEPTEURS DE LA CAPSICINE
Discovery of Novel 6,6-Heterocycles as Transient Receptor Potential Vanilloid (TRPV1) Antagonists
摘要:
The transient receptor potential cation channel, subfamily V, member 1 (TRPV1) is a nonselective cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation in an attempt to identify novel agents for pain treatment. The design and synthesis of a series of novel TRPV1 antagonists with a variety of different 6,6-heterocyclic cores is described, and an extensive evaluation of the pharmacological and pharmacokinetic properties of a number of these compounds is reported. For example, the 1,8-naphthyridine 52 was characterized as an orally bioavailable and brain penetrant TRPV1 antagonist. In vivo, 52 fully reversed carrageenan-induced thermal hyperalgesia (CITH) in rats and dose-dependently potently reduced complete Freund's adjuvant (CFA) induced chronic inflammatory pain after oral administration.
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
[EN] ARYLALKYLAMINO-SUBSTITUTED QUINAZOLINE ANALOGUES<br/>[FR] ANALOGUES QUINAZOLINE A SUBSTITUTION D'ARYLALKYLAMINO
申请人:NEUROGEN CORP
公开号:WO2005087227A1
公开(公告)日:2005-09-22
Arylalkylamino-substituted quinazoline analogues are provided, of the Formula wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
[EN] 4 - HETEROBICYCLYAMINO - SUBSTITUTED QUINAZOLINES AND ANALOGUES THEROF AS CAPSAICIN - ANTAGONISTS<br/>[FR] DERIVES DE QUINAZOLIN-4-YLAMINE BICYCLIQUE SUBSTITUE
申请人:NEUROGEN CORP
公开号:WO2005023807A3
公开(公告)日:2005-04-21
[EN] 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS<br/>[FR] ANALOGUES DE QUINAZOLIN-4-YLAMINE 2-SUBSTITUEE COMME MODULATEURS DES RECEPTEURS DE LA CAPSICINE
申请人:NEUROGEN CORP
公开号:WO2004055003A1
公开(公告)日:2004-07-01
Certain 2-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
Discovery of Novel 6,6-Heterocycles as Transient Receptor Potential Vanilloid (TRPV1) Antagonists
作者:Charles A. Blum、Timothy Caldwell、Xiaozhang Zheng、Rajagopal Bakthavatchalam、Scott Capitosti、Harry Brielmann、Stéphane De Lombaert、Mark T. Kershaw、David Matson、James E. Krause、Daniel Cortright、Marci Crandall、William J. Martin、Beth Ann Murphy、Susan Boyce、A. Brian Jones、Glenn Mason、Wayne Rycroft、Helen Perrett、Rachael Conley、Nicola Burnaby-Davies、Bertrand L. Chenard、Kevin J. Hodgetts
DOI:10.1021/jm100051g
日期:2010.4.22
The transient receptor potential cation channel, subfamily V, member 1 (TRPV1) is a nonselective cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation in an attempt to identify novel agents for pain treatment. The design and synthesis of a series of novel TRPV1 antagonists with a variety of different 6,6-heterocyclic cores is described, and an extensive evaluation of the pharmacological and pharmacokinetic properties of a number of these compounds is reported. For example, the 1,8-naphthyridine 52 was characterized as an orally bioavailable and brain penetrant TRPV1 antagonist. In vivo, 52 fully reversed carrageenan-induced thermal hyperalgesia (CITH) in rats and dose-dependently potently reduced complete Freund's adjuvant (CFA) induced chronic inflammatory pain after oral administration.